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Abstract
Aims—Despite continual efforts to develop prognostic and predictive models of colorectal cancer
by using clinicopathological and genetic parameters, a clinical test that can discriminate between
patients with good or poor outcome after treatment has not been established. Thus, the authors aim
to uncover subtypes of colorectal cancer that have distinct biological characteristics associated
with prognosis and identify potential biomarkers that best reflect the biological and clinical
characteristics of subtypes.
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Methods—Unsupervised hierarchical clustering analysis was applied to gene expression data
from 177 patients with colorectal cancer to determine a prognostic gene expression signature.
Validation of the signature was sought in two independent patient groups. The association
between the signature and prognosis of patients was assessed by Kaplan–Meier plots, log-rank
tests and the Cox model.
Results—The authors identified a gene signature that was associated with overall survival and
disease-free survival in 177 patients and validated in two independent cohorts of 213 patients. In
multivariate analysis, the signature was an independent risk factor (HR 3.08; 95% CI 1.33 to 7.14;
p=0.008 for overall survival). Subset analysis of patients with AJCC (American Joint Committee
on Cancer) stage III cancer revealed that the signature can also identify the patients who have
better outcome with adjuvant chemotherapy (CTX). Adjuvant chemotherapy significantly affected
disease-free survival in patients in subtype B (3-year rate, 71.2% (CTX) vs 41.9% (no CTX);
p=0.004). However, such benefit of adjuvant chemotherapy was not significant for patients in
subtype A.
Conclusion—The gene signature is an independent predictor of response to chemotherapy and
clinical outcome in patients with colorectal cancer.
INTRODUCTION
Colorectal cancer is one of the most common cancers in the USA and the rest of the world,
accounting for an estimated 146 900 new cases and 49 920 deaths in 2009 in the USA
alone.12 Although surgical resection is highly effective for patients with early-stage colon
cancers, a high proportion of patients have relapse after complete surgical resection, with
40% to 50% of patients with stage III disease experiencing such relapse within 5 years.34
Development of various chemotherapy regimens including 5-fluorouracil, oxaliplatin and
irinotecan as the preferred treatment has considerably improved tumour response rate and
median overall survival (OS).56 The use of recently developed targeted drugs such as
cetuximab and bevacizumab in combination with chemotherapy has further improved the
survival of patients with advanced colon cancer.78 However, there is considerable
clinicopathological heterogeneity among the tumours. In addition, tumours with similar
histopathological appearance can follow significantly different clinical courses.
Approximately 50% of patients with advanced colon cancer have a radiographic response
after systemic chemotherapy.5 Thus, for better patient care and management, it is important
to understand any molecular heterogeneity significantly associated with this differential
response to chemotherapy and to develop models to predict those patients who would
benefit the most or least. Clinicopathological staging systems (both American Joint
Committee on Cancer (AJCC) and Dukes staging) have been the gold standard for
prognostication.9 However, they offer little information about response to treatment in
individual patients or about potential therapeutic targets.
Recent advances in technology allow us unbiased genome-wide screening of potential
markers or gene expression signatures that might well reflect prognosis. This approach has
shown potential success in the study of breast cancer.10 In the current study, by applying a
genome-wide survey of gene expression data, we attempted to distinguish subtypes of colon
cancer that have distinct biological characteristics associated with prognosis and to identify
potential biomarker genes or a gene expression signature that best reflects the biological and
clinical characteristics of each subtype. We further tried to establish a prediction model to
help guide treatment strategies for patients after surgery, which can select the patients who
need further treatment due to the aggressive biological characteristics of their disease. Here,
we report on a limited number of genes whose expression patterns can predict the survival of
patients as well as their response to chemotherapy.
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METHODS
Patients and gene expression data
All clinical and gene expression data are available from the National Center for
Biotechnology Information Gene Expression Omnibus database
(http://www.ncbi.nlm.nih.gov/geo). Gene expression data from the Moffit Cancer Center
(Moffit cohort, GSE17536, n=177) were used as the exploration data set.11 Gene expression
data from the Vanderbilt Medical Center (GSE17537, n=55) and Max Planck Institute
(GSE12945, n=62) were pooled and used as the first validation data set (Vanderbilt and Max
Planck (VMP) cohort, n=117).1112 Gene expression data from the Royal Melbourne
Hospital that is part of GSE14333 (n=96) were used as the second validation data set.13
Gene expression data of these patients were redeposited as an independent data set to Gene
Expression Omnibus (GSE29971). To test the prognostic significance of gene expression
signatures, we used only gene expression data with available patient survival data. Although
three prognostic variables (OS, disease-specific survival and disease-free survival (DFS))
were available for the Moffit cohort, only OS and DFS data were available for the VMP and
Melbourne cohorts, respectively.
Adjuvant chemotherapy data were available only for the Moffit, Vanderbilt Medical Center
and Melbourne cohorts. Of the 328 patients in the Moffit, Vanderbilt and Melbourne
cohorts, 147 (2 in AJCC stage I, 28 in stage II, 81 in stage III and 36 in stage IV) had
received standard adjuvant chemotherapy (either single-treatment 5-fluorouracil/
capecitabine or a combination of 5-fluorouracil and oxaliplatin). The remaining patients did
not receive chemotherapy (n 168) or treatment data were not available (n=13). DFS was
defined in a previous study as the time from surgery to the first confirmed relapse and
censored when a patient died or was alive without recurrence at last contact.13
Statistical analysis of microarray data
BRB-ArrayTools (http://linus.nci.nih.gov/BRB-ArrayTools.html) were used primarily for
statistical analysis of gene expression data,14 and all other statistical analyses were
performed in the R language environment (http://www.r-project.org). All gene expression
data were generated by using the Affymetrix U133 version 2.0 platform except for the Max
Planck Institute cohort. Data from the Max Planck Institute were generated by using the
Affymetrix U133A platform. Raw data were downloaded from public databases and
normalised using a robust multi-array averaging method.15 We identified genes that were
differentially expressed among the two classes using a random-variance t test. Differences of
gene expression between two classes were considered statistically significant if their p value
was less than 0.001. A stringent significance threshold was used to limit the number of false-
positive findings. We also performed a global test of whether the expression profiles
differed between the classes by permuting the labels of which arrays corresponded to which
classes. For each permutation, the p values were recomputed and the number of genes
significant at the 0.001 level was noted. The proportion of the permutations that gave at least
as many significant genes as with the actual data was the significance level of the global test.
Cluster analysis was performed with Cluster and TreeView.16
To predict the class of the independent patient cohort, we adopted a previously developed
model using different algorithms.17–19 In order to integrate each data set for constructing
prediction models, we aligned gene features in each data set according to Affymetrix probe
ID. Although 114 probes were identified as candidate probe set for constructing prediction
models in t test analysis, we constructed master prediction models by using gene expression
data from 80 probes for both validation sets because only 80 probes are shared in both
U133A and U133 v2.0 due to the different probe size of microarray platforms. In addition,
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we used the full probe (114 probes) model for the second validation set (Melbourne) to
assess the difference between two prediction models. Gene expression data from different
cohorts were independently centralised by subtracting mean expression value across samples
before pooling them together for building prediction models. Then, gene expression data in
the training set (Moffit cohort) were combined to form a classifier according to a given
algorithm (compound covariate predictor (CCP),20 linear discriminant analysis (LDA)21 or
Bayesian compound covariate predictor (BCCP)).22 Full mathematical description of three
prediction models is available in the supplementary methods and the assembled data set used
for constructing prediction models is also available as supplementary data. The robustness of
the classifier was estimated by the misclassification rate determined during the leave-one-
out cross-validation (LOOCV) in the training set. For each prediction, training of classifier
was done independently and misclassification rate was calculated during each training.
When applied to the independent validation sets (VMP and Melbourne cohorts), prognostic
significance was estimated by Kaplan–Meier plots and log-rank tests between two predicted
subgroups of patients. After LOOCV, the sensitivity and specificity of prediction models
were estimated by the fraction of samples correctly predicted. Multivariate Cox proportional
hazard regression analysis was used to evaluate independent prognostic factors associated
with survival, and gene signature, tumour stage and pathological characteristics were used as
covariates. Cox proportional hazard regression model was also used to analyse the
interaction between subgroups and adjuvant chemotherapy treatment. A p value of less than
0.05 was considered to indicate statistical significance, and all tests were two tailed. All
subset analyses are based on predicted outcome with the 80-probe model.
Gene set and gene network analysis
Ingenuity Pathways Analysis (IPA; Ingenuity Systems, http://www.ingenuity.com) was used
for gene set enrichment analysis and gene network analysis. Gene set enrichment analysis
was carried out to identify the most significant gene sets associated with disease process,
molecular and cellular functions and normal physiological and development condition in
114 prognostic genes as described in the instruction from Ingenuity Systems. The
significance of over-represented gene sets was estimated by the right-tailed Fisher's exact
test. Gene network analysis was carried out by using a global molecular network developed
from information contained in the Ingenuity Knowledge Base. Eight hundred and eighty-two
gene features were mapped to the Ingenuity Knowledge Base. Identified gene networks were
ranked according to scores provided by IPA. The score is the likelihood of a set of genes
being found in the networks due to random chance. For example, a score of 3 indicates that
there is a 1/1000 chance that the focus genes are in a network due to random chance.
RESULTS
Significant association of prognosis with two subgroups found by hierarchical clustering
To uncover potential subgroups of colorectal cancer, we applied hierarchical clustering
analysis to gene expression data (table 1, Moffit cohort, n=177) and found two major
subgroups of colorectal cancer (supplementary figure S1). When the association of the two
subgroups with clinical variables was examined, significant association with the two
subgroups was apparent only for patient survival (supplementary table S1, 53% vs 29%,
p=0.0007, by χ2 test). As expected, Kaplan–Meier plots and the log-rank test showed
significant differences in all prognostic variables including OS and DFS (p=5.6×10–4 and
p=0.01, respectively, by log-rank test; figure 1).
We next sought to identify a limited number of genes whose expression is tightly associated
with the two subgroups. By applying a stringent threshold cut-off (p<0.001 and twofold
difference), we identified 114 gene features (supplementary figure S2 and supplementary
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table S2). Interestingly, expressions of SPP1 and POSTN, previously reported as metastasis
genes and associated with poor prognosis in colon cancer,2324 were much higher in the poor
prognosis subgroup B. To uncover biological characteristics enriched in 114 genes, we
carried out gene set enrichment analysis with IPA. As expected, it revealed enrichment of
genes whose function is highly associated with cancer, cell growth and proliferation and
tumour morphology (supplementary figure S3), indicating that selected genes might well
reflect the biological characteristics of the two subgroups of colon cancer.
Validation of the prognostic gene expression signature in independent cohorts
Having in hand a distinct gene expression signature (114 genes) that well reflects the
prognosis of patients with colorectal cancer, we next sought to validate the association of the
signature with prognosis in independent patient cohorts. For this validation, gene expression
data from the Vanderbilt Medical Center (n=55) and Max Planck Institute (n=62) were
pooled (VMP cohort, n=117), and previously established data training and prediction
methods were applied and gene expression data from the Moffit cohort were used for
training of classifiers. Because 80 probes are common to all training and validation sets,
gene expression data from 80 probes were used for constructing the prediction model. When
patients with colon cancer in the VMP cohort were stratified according to a cluster-specific
gene expression signature, Kaplan–Meier plots showed significant differences (p=0.032 by
log-rank test) in OS of patients between the two subtypes that were predicted by CCP (figure
2). Specificity and sensitivity for correctly predicting subtype B in the test set (Moffit
cohort) during LOOCV were 0.826 and 0.868, respectively. When CCP was replaced by
different prediction algorithms such as LDA and BCCP, the prognostic difference between
the two subgroups remained significant (p=0.04 and p=0.005 by log-rank test for LDA and
BCCP, respectively).
We next performed subset analysis only with patients with stage II or stage III cancer. In
subset analysis, the gene expression signature successfully identified patients with poor
survival among those with stage II and stage III cancer (supplementary figure S4),
supporting the notion that the gene expression signature is independent of the current staging
systems. Univariate and multivariate Cox proportional hazards regression analyses were
undertaken in the VMP cohort to evaluate the prognostic value of the gene expression
signature in combination with other clinical variables including patient age at diagnosis,
AJCC stage, sex and grade. In the univariate analysis, the gene signature and AJCC stage
were significantly associated with OS (p=0.036 and p=1.16×10–7, respectively). In the
multivariate analysis, AJCC stage and gene signature still maintained the significance
(p=1.59310 5 and p=0.008), and the grade showed marginal significance (p=0.04) (table 2).
To further test the robustness of the gene expression signature, we applied the 80-probe
prediction model to a second validation cohort (Melbourne cohort, n=96). Similar to the
results for the two previous cohorts, there is a substantial trend of association with prognosis
(supplementary figure S5B). When the full probe model (114 probes) was applied, the
association of signature with prognosis became more significant (supplementary figure
S5B). In the univariate analysis with predicted outcome from the 114-probe model, the gene
signature and AJCC stage were significantly associated with DFS (p=0.048 and p=0.002,
respectively), and significance remains similar in the multivariate analysis (p=0.049 and
0.002, respectively) (supplementary table S3).
Significant association of the signature with DFS of patients after adjuvant chemotherapy
Adjuvant chemotherapy data were available for 328 of the 390 patients from the three
cohorts. We therefore sought to determine the association of the new prognostic gene
expression signature (80-probe model) with response to chemotherapy. As expected, the
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difference in DFS between the two subtypes remained significant in the combined subset of
patients (3-year rate, 89.1% (A) vs 74.6% (B); p=7.8×10–4 by log-rank test, figure 3A) after
excluding patients with stage IV cancer. The HR of subtype B for relapse was 2.7 (95% CI
1.47 to 4.79; p=0.001). To examine the association of the signature with response to
adjuvant chemotherapy, we performed subset analysis with patients in AJCC stage III
(n=109), a stage for which the benefit of adjuvant chemotherapy has been well
established.25–27 Patients with stage III disease were subdivided into two subtypes (A or B),
and the difference in DFS was independently assessed. Adjuvant chemotherapy significantly
affected DFS in patients in subtype B (3-year rate, 71.2% (CTX) vs 41.9% (no CTX);
p=0.004 by log-rank test, figure 3C). However, such benefit of adjuvant chemotherapy was
not significant for patients in subtype A (3-year rate, 85.4% (CTX) vs 75.2% (no CTX);
p=0.5 by log-rank test, figure 3D). When Cox regression model was applied, the interaction
of subtypes with adjuvant chemotherapy reached a significance level of 0.36 (supplementary
figure S6). However, consistent with the Kaplan–Meier plot and log-rank test, the estimated
HR for adjuvant chemotherapy in subgroup B was 0.31 (95% CI 0.14 to 0.73; p=0.007),
while HR for relapse for adjuvant chemotherapy in subtype A was 0.67 (95% CI 0.19 to
2.34; p=0.5).
Biological insight of prognostic and predictive signature
Although the 114-gene expression signature was robust enough to discriminate between
patients in all three different cohorts, the number of genes was too small to develop a gene
network analysis, because we applied an extremely stringent cut-off (p<0.001 and twofold)
to avoid any potential false-positive problem during signature-based prediction. Thus, to
explore the biological characteristics of subgroups with poorer prognosis (patients in
subtype B), we attempted to identify genes whose expression patterns were conserved in all
three cohorts. To maximise the compatibility of the three data sets, we included only gene
expression data generated by using the Affymetrix U133 v2.0. Gene lists X, Y and Z (figure
4A) represent the 882 genes that were differentially expressed between subgroups A and B
in all three cohorts.
We next performed pathway analysis on the 882 genes in the extended gene list (figure 4B)
using the IPA tool (supplementary table S4). This analysis revealed a series of putative
networks. Functional connectivity of the top network revealed a strong over-representation
of TGFβ pathways (supplementary figure S7), suggesting that its activation might be a key
genetic determinant associated with poorer survival of patients with colon cancer in subtype
B. In addition, genes involved in the activation of the NF-κB pathway, a key survival
pathway in many cancers, are overexpressed in subtype B colon cancer (supplementary
figure S8), suggesting that activation of NF-κB might be, in part, accountable for poorer
survival of patients in subtype B. Interestingly, two genes in the NF-κB network are FYN
and LYN–part of SRC tyrosine kinase family–whose activity are frequently increased and
well associated with metastasis potential and poorer outcome in colon cancer.2829
DISCUSSION
By analysing gene expression data from colorectal cancer tissues, we identified a limited
number of genes that are significantly associated with prognosis. Robustness of the signature
was validated in two independent cohorts. Subset analysis with only patients with stage III
cancer indicated that the signature might be associated with the benefit of adjuvant
chemotherapy. Current staging systems and biomarkers are very limited in providing
therapeutic guidance to patients with colorectal cancer. Our gene expression signature may
open up new opportunities to develop molecular stratification of patients and provide
treatment guidance.
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We applied two independent but complimentary methods to construct the signature, test its
robustness and validate its association with clinical outcomes. In the first approach, we used
unsupervised clustering to identify subgroups that differed with respect to gene expression
patterns. Subsequent analysis with clinical data revealed that the two subgroups differed
significantly in OS and DFS, indicating that biological characteristics reflected in gene
expression patterns may well represent clinical heterogeneity that has not been properly
addressed in the current staging systems. In a second approach, we applied supervised
prediction models to validate the association of the signature with clinical outcomes in two
independent patient cohorts. The robustness of the 114-gene signature that we studied was
supported by the high sensitivity (>0.8) and spec-ificity (>0.8) during training of prediction
models within the Moffit cohort and a significant association of predicted outcome with
patient prognosis in both test cohorts (figure 2 and supplementary figure S5).
Subset analysis of patients with available chemotherapy data suggested that the 114-gene
signature might be able to predict which patients would benefit from adjuvant
chemotherapy. In patients with stage III disease, 5-fluorouracil-based chemotherapy was
significantly associated with improved outcome for patients in subtype B (HR 0.31; 95% CI
0.14 to 0.73; p=0.007), whereas its benefit was not statistically significant for patients in
subtype A. Thus, our newly identified gene signature showed a mixed prognostic and
predictive association in the current study. This mixed association is in good agreement with
previous findings in breast cancer showing that a strong prognostic recurrence score based
on the Oncotype DX assay is highly predictive for response to chemotherapy as well.1030
Although an OS benefit for 5-fluorouracil-based adjuvant chemotherapy has been
established for patients with AJCC stage III cancer,252631 the use of adjuvant chemotherapy
remains controversial for patients with AJCC stage II disease. The QUick and Simple And
Reliable (QUASAR) trial reported a modest but statistically significant improvement in DFS
in patients with stage II cancer treated with 5-fluorouracil-based adjuvant chemotherapy
compared with observation.32 However, no additional trials have been performed
appropriately to validate it in patients with stage II cancer, owing in part to the large sample
size that would be required. It has been suggested that at least 9680 patients per group would
be required to detect a 2% survival difference between the treatment and control arms, with
90% power and a 0.05 significance level.33 The findings of QUASAR and other pooled
analyses suggest that there might be a subset of patients with stage II cancer at high risk of
recurrence who might benefit from 5-fluorouracil-based adjuvant chemotherapy. Our
analysis was limited to patients with stage III cancer because the number of patients with
stage II disease who received chemotherapy was too small in our current study cohort. The
use of new predictive gene signatures may help reduce the number of patients needed in
prospective clinical trials to estimate the benefit of chemotherapy in patients with stage II
cancer by identifying patients at higher risk in advance of treatment.
Molecular functions of genes upregulated in subtype B were in good agreement with clinical
characteristics of that subtype. Interestingly, network analysis revealed that many of these
genes were under the control of the TGFβ pathway, which is frequently associated with
metastasis in many types of cancers by promoting epithelial and mesenchymal
transition.3435 Activation of SRC family kinases in poorer prognostic subtype is in good
agreement with previous studies showing that SRC or its related kinase activity increases in
colorectal tumours relative to adjacent mucosa, with the highest activity observed in
metastases, and correlates inversely with patient survival.2836 Therefore, these genes
overexpressed in patients with subtype B well reflect the aggressiveness of colorectal cancer
cells. SRC-targeted agents, which are now in advanced clinical development for patients
with solid tumours, might be good candidates for targeted treatment for patients in subtype
B.37
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Several previous studies have tried to identify prognostic gene expression signatures.
Twenty-three-gene and 30-gene prognostic signatures were independently developed to
predict recurrence in patients with AJCC stage II disease.3839 However, these signatures
have not been validated in independent patient groups by other investigators and cannot
predict the response to adjuvant chemotherapy. A recent study developed a risk score of
recurrence based on evolutionarily conserved 34 genes.11 Although its independence over
the use of stage has not been firmly established, a 128-gene signature was identified as a
marker for the genomic stage of colorectal cancer and was well associated with prognosis.13
A new multi-gene expression assay for colon cancer, known as Oncotype DX, has been
introduced with the aim of improving treatment decisions, especially for patients with stage
II disease.40 Although this seven-gene prognostic marker was validated in the QUASAR
cohort, the chemotherapy-benefit gene signature was not validated in the same cohort.
Interestingly, of the seven genes in the prognostic Oncotype DX, three (FAP, INHBA and
BGN) are present in our extended gene list (figure 4), suggesting that there might be partial
overlap between our prognostic subtypes (A and B) and the high- and low-risk groups
identified by the Oncotype DX recurrence score.
Our new signature may overcome the current limitation of biomarkers of colorectal cancer.
Among several interesting biomarkers linked with clinical outcomes of patients with
colorectal cancer,41 microsatellite instability (MSI) is the only prognostic marker validated
in multiple studies and independently of stage.4243 Although the predictive values of MSI to
adjuvant chemotherapy and of KRAS mutations to the use of epidermal growth factor
receptor inhibitors have been established, these markers are only useful as negative markers
for treatments.4445 Thus, these markers fail to predict which patients will benefit from
treatments.
While it is interesting to see the association of the signature with the potential benefit of
adjuvant chemotherapy in patients with stage III colorectal cancer, the predictive nature of
the signature is not firmly established yet since interaction of subgroup with adjuvant
chemotherapy (or heterogeneity of two subgroups over adjuvant chemotherapy) did not
reach significance level (supplementary figure S6). However, due to the small number of
patients used in the analysis, it would be too premature to draw a strong conclusion for the
predictive nature of the signature. Although significant, our multivariate analysis (table 2)
has also some limitations since other known predictors of prognosis in colorectal cancer
such as the refined TN substages, MSI status and number of examined nodes are not
included. Thus, the significance and robustness of the signature as prognostic markers and
predictive markers for adjuvant chemotherapy remain to be determined in future studies.
In conclusion, we identified two new prognostic subtypes of colorectal cancer that showed a
significant difference in the survival of patients. The gene signature could predict the
response to adjuvant chemotherapy. This study clearly demonstrated that our gene signature
reflects the molecular characteristics of patients with colorectal cancer and provides us an
opportunity for the rational design of future clinical trials for testing the benefit of adjuvant
chemotherapy for patients with stage II and ultimately stage III colorectal cancer. This
result, if confirmed in prospective studies, might improve patient care by providing more
practical guidance for different treatments.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Significance of this study
What is already known on this subject?
▶ Colorectal cancer is a clinically heterogeneous disease, and its heterogeneity has
not been characterised at the molecular level
▶ The benefit of adjuvant chemotherapy for patients with stage II colorectal cancer
is not well established
▶ There are no clinically useful biomarkers that can reliably predict the prognosis
and response to adjuvant chemotherapy
What are the new findings?
▶ There seem to be distinct subtypes of colorectal cancer that are well associated
with prognosis of patients
▶ Expression signature of 114 genes that best reflect the difference between two
subtypes can predict the likelihood of the benefit of adjuvant chemotherapy
especially in patients with AJCC (American Joint Committee on Cancer) stage III
disease
▶ Prognostic and potentially predictive gene expression signature is present at the
time of diagnosis
How might it impact on clinical practice in the foreseeable future?
▶ The use of gene expression profiling can improve the molecular classification of
patients with colorectal cancer by adding to the existing classifications
▶ The gene expression signature might be useful markers for identifying patients
with stage II disease who would have the benefit of adjuvant chemotherapy in a
prospective study
▶ It will open up new opportunities for personalised treatment of patients with
colorectal cancer based on stratification by prognostic and predictive gene
expression signature
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Figure 1.
Kaplan–Meier plots of the prognosis of patients with colon cancer in the Moffit cohort.
Patients were stratified according to American Joint Committee on Cancer (AJCC) stage or
gene expression patterns (two clusters). Disease free survival data from 32 patients are not
available.
Oh et al. Page 13
Gut. Author manuscript; available in PMC 2012 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2.
Construction of prediction model in the test cohort according to gene expression signatures
from the Moffit cohort. (A) Schematic overview of the strategy used for the construction of
prediction models and evaluation of predicted outcomes based on gene expression
signatures. (B) Kaplan–Meier plots of OS. Patients were stratified according to AJCC stage
or two subgroups predicted by CCP. p Values were obtained from the log-rank test. The ‘+’
symbols in the panels indicate censored data. AJCC, American Joint Committee on Cancer;
CCP, compound covariate predictor; OS, overall survival.
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Figure 3.
Significant association of two subtypes with adjuvant chemotherapy. (A) Kaplan–Meier
plots of disease-free survival (DFS) of patients with colorectal cancer in the combined
cohort. Patients were plotted according to the prognostic expression signature of 80 genes
(two subtypes). Patients in stage I, those in stage II and those in stage III with available
adjuvant chemotherapy data were included for analysis (n=266). (B) Kaplan–Meier plots of
DFS of patients with colorectal cancer in the combined cohort (patients in stage III, n=109).
(C) Kaplan–Meier plots of patients in subtype B with stage III disease (n=59). Patients were
plotted according to presence and absence of adjuvant chemotherapy (CTX). (D) Kaplan–
Meier plots of patients in subtype A with stage III disease (n=50). Patients were plotted
according to presence and absence of adjuvant chemotherapy (CTX).
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Figure 4.
Subtype-specific gene expression patterns conserved in all three cohorts of patients with
colorectal cancer. (A) Venn diagram of genes with expression that differed significantly
between patients with colorectal cancer in subtypes A and B in the three different cohorts.
Univariate test (two-sample t test) with multivariate permutation test (10 000 random
permutations) was applied. In each comparison, we applied a cut-off p value of less than
0.001 to retain genes with expression that differed significantly between the two groups of
tissues examined. (B) Expression patterns of selected genes shared in the three colon cancer
cohorts. The expressions of only 882 genes were commonly upregulated or downregulated
in all three cohorts. Colored bars at the top of the heat map represent samples as indicated.
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Table 1
Clinical and pathological features of patients with colorectal cancer
Variable Moffit cohort VMP cohort Melbourne cohort
Patients (n) 177 117 96
    Male, n (%) 96 (54) 60 (51) 52 (54)
    Female, n (%) 81 (46) 57 (49) 44 (46)
Age (years)
    Median 66 63 68
    Range 26–92 23–94 30–92
Location, n (%)
    Colon 177 (100) 84 (72) 72 (75)
    Rectum 0(0) 33 (28) 24 (25)
AJCC stage, n (%)
    I 24 (14) 17 (15) 19 (20)
    II 57 (32) 38 (21) 42 (70)
    III 57 (32) 40 (34) 35 (36)
    IV 39 (22) 22 (19) 0 (0)
Grade, n (%)
    1 16 (9) 1 (1)
    2 134 (76) 63 (54)
    3 27 (15) 34 (29)
    NA 19 (16) 96 (100)
Adjuvant chemotherapy, n (%)
    Yes 82 (46) 39 (33) 26 (27)
    No 82 (46) 16 (14) 70 (73)
    NA 13 (8) 62 (53) 0
Number of deaths 72 32 20*
Median follow-up (months) 42.2 48.2 40.2
AJCC, American Joint Committee on Cancer; NA, not applicable; VMP, Vanderbilt and Max Planck.
*
Recurrence.
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Table 2
Univariate and multivariate Cox proportional hazard regression analyses of OS in the VMP cohort (n=117)
Univariate Multivariate
HR (95% CI) p Value HR (95% CI) p Value
Gender (M or F) 0.68 (0.34 to 1.38) 0.29 1.07 (0.43 to 2.61) 0.88
Age (>70) 1.44 (0.97 to 2.9) 0.3 1.68 (0.72 to 3.9) 0.22
AJCC stage (I, II, III, IV) 3.6 (2.24 to 5.79) 1.16 × 10–7 2.9 (1.82 to 4.93) 1.59 × 10–5
Grade (1, 2, 3) 1.72 (0.8 to 3.69) 0.16 2.31 (1.03 to 5.2) 0.04
Gene signature (A or B) 2.1 (1.0 to 4.3) 0.036 3.08 (1.33 to 7.14) 0.008
AJCC, American Joint Committee on Cancer; F, female; M, male; OS, overall survival; VMP, Vanderbilt and Max Planck.
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